Brief: Gracell Announces FDA Clearance Of Application For Phase 1/2 Clinical Trial Of FasTCAR-T GC012F For Treatment Of Refractory Systemic Lupus Erythematosus
27/11/2023 14:38
Nov 27 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES ANNOUNCES FDA CLEARANCE OF IND
APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF FASTCAR-T GC012F FOR
THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Source text for Eikon: ID:nGNX2XkDbn
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27